Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.
about
Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid LeukemiaTargeting acute myeloid leukemia with TP53-independent vosaroxin.Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models.Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo.The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabineVosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemiaA "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone.Vosaroxin : a novel antineoplastic quinolone.Developmental therapeutics in acute myelogenous leukemia: are there any new effective cytotoxic chemotherapeutic agents out there?1,8-Naphthyridine Derivatives: A Review of Multiple Biological Activities.The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review.Synthesis and potential antitumor activity of 7-(4-substituted piperazin-1-yl)-4-oxoquinolines based on ciprofloxacin and norfloxacin scaffolds: in silico studies.Synthesis, cytotoxicity and mechanistic evaluation of 4-oxoquinoline-3-carboxamide derivatives: finding new potential anticancer drugs.The preclinical discovery of vosaroxin for the treatment of acute myeloid leukemia.Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML?Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II.Iron(III)-binding of the anticancer agents doxorubicin and vosaroxin.
P2860
Q28072058-4A89E388-64DE-4418-93A2-AE7ECE8312C3Q30245472-5331DFCB-983E-40C0-B7FD-A268182691A1Q33728180-A1C90C7B-7ECC-467E-B082-2824F271CA69Q34063560-23AB506A-DAB5-4375-87C0-AD76553FB482Q34612613-E5531461-6994-4B55-BCD0-946582F66716Q35954771-9F406CD4-4325-46DD-8ABC-5C0B2405E607Q36078593-D4129A89-9534-4A98-9A44-D0D78118FE56Q37204002-BEB3FEA4-BD04-4B13-9DE8-50347FD1EF3BQ38020911-79C2B622-5220-457E-B52B-D1A470CFB360Q38103753-4EDA5803-5601-4B01-99AA-81D1BABDEB74Q38628084-FEE3BC76-48E5-4A01-9F32-F1E0C24D4449Q38829544-3A28E765-999D-4CF2-B96F-BFD4DF4D546FQ38847831-326DA44E-0EFB-49D0-AFC6-64BC702A7B35Q38992031-E10622C2-DC95-449D-ACF1-BC3370FD17D5Q39306416-0868EE48-F47F-4BAC-8775-B8BD039299B7Q39416207-476CE1EF-71EE-463F-99F6-CB446CC74E83Q46425542-168691B1-D336-4CFE-B356-4AA7BAC491B8Q46795289-9FAC69F2-2EE2-4B9E-8DA2-78C9253B6A40
P2860
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Voreloxin, a first-in-class an ...... eport on two dosing schedules.
@ast
Voreloxin, a first-in-class an ...... eport on two dosing schedules.
@en
type
label
Voreloxin, a first-in-class an ...... eport on two dosing schedules.
@ast
Voreloxin, a first-in-class an ...... eport on two dosing schedules.
@en
prefLabel
Voreloxin, a first-in-class an ...... eport on two dosing schedules.
@ast
Voreloxin, a first-in-class an ...... eport on two dosing schedules.
@en
P2093
P1476
Voreloxin, a first-in-class an ...... eport on two dosing schedules.
@en
P2093
Craig J Berman
Daniel C Adelman
David S Mendelson
Heather A Wakelee
Herbert I Hurwitz
Jeffrey A Silverman
Judith A Fox
Michael S Gordon
Nancy A Havrilla
Ranjana H Advani
P304
P356
10.1158/1078-0432.CCR-09-2236
P407
P577
2010-03-16T00:00:00Z